Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Andelyn Biosciences and Odylia Therapeutics Partner to Manufacture Novel Gene Therapy for Vision Loss

    Jan 31, 2023, 10:28 AM by
    Novel AAV Capsid Anc80 enables efficient gene transfer
    Full story
  • ZeOmega Reports Record Demand and Growth for PHM Solution in 2022

    Jan 31, 2023, 10:19 AM by
    New and Expanded Agreements with Major Healthcare Organizations Underscore ZeOmega as Go-to Resource for Population Health Management
    Full story
  • TC Biopharm adds Bree Harlin as Chief Clinical Officer to Lead Global Clinical Division

    Jan 31, 2023, 10:15 AM by
    Former Loxo@Lily exec Bree Harlin has been appointed CCO by TC BioPharm to oversee expansion of U.S. FDA clinical Trials.
    Full story
  • Retinal Organoid-Derived Neurons to Potentially Cure Degenerative Eye Disease

    Jan 31, 2023, 01:00 AM by User Not Found
    Bio-IT World | A new study published in the Proceedings of the National Academy of Science demonstrates the potential for lab-grown retinal neurons to reestablish synaptic function and cure neurodegenerative eye disease, according to researchers from the University of Wisconsin–Madison.
    Full story
  • Verisense Health, a Shimmer Research Spin-off, Launches as a Digital Health Software and Data Management Company

    Jan 30, 2023, 10:30 AM by
    Verisense® Health, Inc. launched today as a digital health software and data management company. It was established with the goal of providing sponsors with cost-efficient access to a digital biobank of longitudinal raw patient data. The new company is a spin-off from Dublin-based wearable technology services and sensor manufacturer Shimmer Research.
    Full story
  • Creative Proteomics Revised Its Molecular-Interaction Subsite for a Better User Experience

    Jan 30, 2023, 10:28 AM by
    Full story
  • Creative Proteomics Lipidomics Upgrades Its Medium-Chain and Long-Chain Fatty Acids Analysis Service

    Jan 30, 2023, 10:28 AM by
    Full story
  • Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution

    Jan 30, 2023, 10:27 AM by
    Full story
  • Exosome Research—Impeding into an Epoch of Bursting Development

    Jan 30, 2023, 10:27 AM by
    A recent market report reveals the huge potential of exosome research, which is gaining mounting research fever across the industry.
    Full story
  • CD BioGlyco Developed Various Strategies for Sialic Acid Analysis

    Jan 30, 2023, 10:26 AM by
    Full story
  • Creative Biostructure Provides iEM Platform for Viral Research

    Jan 30, 2023, 10:22 AM by
    Full story
  • MicrobioSeq’s Plasmid Identification Service Boosts Microbial Characterization Research

    Jan 30, 2023, 10:21 AM by
    Full story
  • CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research

    Jan 30, 2023, 10:21 AM by
    Full story
  • CD Genomics Introduces Professional and Mature Long Amplicon Analysis Service

    Jan 30, 2023, 10:21 AM by
    Full story
  • Huateng Pharma Supplies CAS NO.864731-61-3 in Large Quantities

    Jan 30, 2023, 10:11 AM by
    About Huateng Pharma Huateng Pharma is a leading and professional manufacturer which can provide APIs, pharmaceutical intermediates, PEG derivatives, biochemical reagents, Vitamin D Derivatives and so on. We have established a 5000 square meters R&D center and have our own manufacturing site covering 34,000 square meters. Contact us Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818
    Full story
  • Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results

    Jan 27, 2023, 09:49 AM by
    Full story
  • Take the DNA Delorean: The Promise of Large Language Models in Genomics

    Jan 27, 2023, 01:00 AM by User Not Found
    Bio-IT World | Information directly from DNA to understand RNA's and human proteins' downstream structure describes how our cells function in clear linguistic terms. Today, large language models demonstrate remarkable abilities to interpret, translate, summarize, and generate human languages. Now, we are finally generating the amount of data required to train such models in the language of biology.
    Full story
  • iVexSol Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors

    Jan 26, 2023, 09:50 AM by
    Full story
  • Kroger Health Establishes Clinical Trial Site Network to Increase Reach and Access to Research Studies

    Jan 26, 2023, 09:50 AM by
    Announcement comes with the collaboration with biopharmaceutical industry to introduce colorectal cancer clinical trial
    Full story
  • Microsoft Applies AI to Digitial Cancer Pathology Imaging, World’s First Next-Generation Single-Molecule Protein Sequencing Platform, More

    Jan 26, 2023, 01:00 AM by User Not Found
    Bio-IT World | A Salmonella-based bactofection platform to deliver RNA payloads to treat cancer patients; tRNA therapeutics capable of overcoming genetic errors to treat genetic diseases and cancer; the Jackson Laboratory enters an expansive and exclusive intellectual property licensing agreement across six areas of human health; and more.
    Full story
  • «
  • 91
  • 92
  • 93
  • 94
  • 95 (current)
  • 96
  • 97
  • 98
  • 99
  • 100
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy